Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge

[1]  R. Bronson,et al.  Inhibition of EGFR Induces a c‐MET‐Driven Stem Cell Population in Glioblastoma , 2014, Stem cells.

[2]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[3]  David T. W. Jones,et al.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.

[4]  H. Gan,et al.  The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered , 2013, The FEBS journal.

[5]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[6]  Barbara S. Paugh,et al.  Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. , 2013, Cancer research.

[7]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[8]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.

[9]  David Haussler,et al.  Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. , 2013, Cancer research.

[10]  T. Mikkelsen,et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[12]  D. Brat,et al.  PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.

[13]  J. Huse,et al.  Evaluation of Histone 3 Lysine 27 Trimethylation (H3K27me3) and Enhancer of Zest 2 (EZH2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas , 2013, Brain pathology.

[14]  W. Yung,et al.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.

[15]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[16]  D. Pe’er,et al.  RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. , 2013, Cancer research.

[17]  G. Reifenberger,et al.  Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations , 2013, Clinical Cancer Research.

[18]  Raul Rabadan,et al.  The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.

[19]  J. Hagan,et al.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. , 2013, Biochimica et biophysica acta.

[20]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[21]  Miguel Melo,et al.  Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.

[22]  M. Ross,et al.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.

[23]  Rainer König,et al.  BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 , 2013, Nature Medicine.

[24]  Ken Chen,et al.  A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. , 2013, Genes & development.

[25]  K. Ichimura,et al.  Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss , 2013, Acta Neuropathologica.

[26]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[27]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[28]  M. Prados,et al.  Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children , 2013, Child's Nervous System.

[29]  Mindy I. Davis,et al.  ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells , 2013 .

[30]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[31]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[32]  Sabine Mueller,et al.  The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.

[33]  Ryan M. Layer,et al.  Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms , 2013, Genome research.

[34]  A. Ashworth,et al.  Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. , 2013, Cancer discovery.

[35]  Serdar Bozdag,et al.  Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. , 2013, PloS one.

[36]  Wei Yang,et al.  The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.

[37]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[38]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[39]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[40]  A. Fontebasso,et al.  Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant Histone 3 Tail , 2013, Brain Pathology.

[41]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[42]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[43]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[44]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[45]  P. Span,et al.  Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. , 2013, International journal of radiation oncology, biology, physics.

[46]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[47]  T. Chan,et al.  Valproic acid use during radiation therapy for glioblastoma associated with improved survival. , 2012, International journal of radiation oncology, biology, physics.

[48]  D. Louis,et al.  Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? , 2013, Nature Reviews Clinical Oncology.

[49]  K. Warren.  Diffuse intrinsic pontine glioma: poised for progress , 2012, Front. Oncol..

[50]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[51]  Eric A Bushong,et al.  Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice , 2012, Science.

[52]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[53]  Masao Nagasaki,et al.  Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells , 2012, Proceedings of the National Academy of Sciences.

[54]  P. Malatesta,et al.  Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF‐induced oligodendroglioma , 2012, International journal of cancer.

[55]  S. Inoue,et al.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.

[56]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[57]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[58]  K. Aldape,et al.  PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis , 2012, Cell.

[59]  S. Vandenberg,et al.  Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240 , 2012, Proceedings of the National Academy of Sciences.

[60]  Andrey Korshunov,et al.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.

[61]  A. von Deimling,et al.  Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event , 2012, PloS one.

[62]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[63]  L. Liau,et al.  IDH mutations in human glioma. , 2012, Neurosurgery clinics of North America.

[64]  Darren Hargrave,et al.  Paediatric and adult malignant glioma: close relatives or distant cousins? , 2012, Nature Reviews Clinical Oncology.

[65]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[66]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[67]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[68]  P. Span,et al.  HYPOFRACTIONATION VERSUS CONVENTIONAL RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A MATCHED COHORT ANALYSIS , 2012 .

[69]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[70]  P. Northcott,et al.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. , 2012, Cancer cell.

[71]  S. Al-Sarraj,et al.  Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. , 2012, Cancer research.

[72]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[73]  K. Ichimura.  Molecular pathogenesis of IDH mutations in gliomas , 2012, Brain Tumor Pathology.

[74]  P. Varlet,et al.  Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas , 2012, PloS one.

[75]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[76]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[77]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[78]  W. Vandertop,et al.  Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. , 2012, Cancer treatment reviews.

[79]  Caterina Giannini,et al.  Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. , 2012, Neuro-oncology.

[80]  S. Weiss,et al.  An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.

[81]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[82]  A. Iavarone,et al.  Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. , 2012, Cancer cell.

[83]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[84]  K. Aldape,et al.  ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. , 2012, Nature cell biology.

[85]  R. Verhaak,et al.  Studying a complex tumor: potential and pitfalls. , 2012, Cancer journal.

[86]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[87]  R. Beroukhim,et al.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma , 2012, Journal of Neuro-Oncology.

[88]  Ganesh Rao,et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.

[89]  Derek Y. Chiang,et al.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. , 2011, Cancer research.

[90]  N. Harris,et al.  EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas , 2011, PloS one.

[91]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[92]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Barbara S. Paugh,et al.  Targeted Therapy for BRAFV600E Malignant Astrocytoma , 2011, Clinical Cancer Research.

[94]  J. Kleinman,et al.  Spatiotemporal transcriptome of the human brain , 2011, Nature.

[95]  Barbara S. Paugh,et al.  Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  R. Mirimanoff,et al.  Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma , 2011, Neurology.

[97]  Noemi Andor,et al.  Asymmetry-defective oligodendrocyte progenitors are glioma precursors. , 2011, Cancer cell.

[98]  G. Reifenberger,et al.  Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas , 2011, International journal of cancer.

[99]  E. Holland,et al.  Genetic modeling of gliomas in mice: New tools to tackle old problems , 2011, Glia.

[100]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[101]  J. Y. Lee,et al.  MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA , 2011, Child's Nervous System.

[102]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[103]  L. Luo,et al.  Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma , 2011, Cell.

[104]  Chris Jones,et al.  Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β , 2011, Molecular Cancer Therapeutics.

[105]  T. Ludwig,et al.  Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype , 2011, PloS one.

[106]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[107]  P. Brastianos,et al.  Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis , 2011, Journal of Neuro-Oncology.

[108]  M. Delorenzi,et al.  Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.

[109]  Chunxu Qu,et al.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. , 2011, Cancer cell.

[110]  Daniel J Brat,et al.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[111]  I. Weissman,et al.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma , 2011, Proceedings of the National Academy of Sciences.

[112]  J. Lowe,et al.  Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. , 2011, Neuro-oncology.

[113]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[114]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[116]  G. Reifenberger,et al.  Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010, Acta Neuropathologica.

[117]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[118]  C. Brennan,et al.  PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. , 2010, Genes & development.

[119]  P. Kleihues,et al.  Intratumoral Patterns of Genomic Imbalance in Glioblastomas , 2010, Brain pathology.

[120]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[121]  C. Sarkar,et al.  MGMT gene promoter methylation in pediatric glioblastomas , 2010, Child's Nervous System.

[122]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  F. Giangaspero,et al.  Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas , 2010, Child's Nervous System.

[124]  Alan Mackay,et al.  A DISTINCT SPECTRUM OF COPY NUMBER ABERRATIONS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED PAEDIATRIC HIGH GRADE GLIOMA , 2010 .

[125]  R. Abdel-Fattah,et al.  An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. , 2010, The American journal of pathology.

[126]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[127]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[128]  T. MacDonald,et al.  Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. , 2010, Cancer research.

[129]  A. Montpetit,et al.  Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. , 2010, Neuro-oncology.

[130]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[131]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[132]  A. Álvarez-Buylla,et al.  Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes , 2010, The EMBO journal.

[133]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[134]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[135]  R. Arceci.  Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor α and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets , 2010 .

[136]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[137]  D. Brat,et al.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group , 2010, Child's Nervous System.

[138]  M. Weller,et al.  Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide , 2010, Journal of Neuro-Oncology.

[139]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[140]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[141]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[142]  M. J. van den Bent,et al.  Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.

[143]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Paul Workman,et al.  EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines , 2009, Clinical Cancer Research.

[145]  B. Neyns,et al.  Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[146]  M. Nistér,et al.  GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background , 2009, Glia.

[147]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[148]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[149]  E. Radaelli,et al.  Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. , 2009, Histology and histopathology.

[150]  Y. Wang,et al.  Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. , 2009, Cancer cell.

[151]  E. Holland,et al.  Modeling Adult Gliomas Using RCAS/t-va Technology. , 2009, Translational oncology.

[152]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[153]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  D. Housman,et al.  Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis , 2009, Proceedings of the National Academy of Sciences.

[155]  Susan M. Chang,et al.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  Arturo Alvarez-Buylla,et al.  Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. , 2009, Cancer cell.

[157]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[158]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[159]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  R. Mason,et al.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.

[163]  N. Hashimoto,et al.  Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis , 2007, Clinical Cancer Research.

[164]  S. Albrecht,et al.  Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma , 2007, Clinical Cancer Research.

[165]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[166]  T. Soussi,et al.  Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors , 2007, Journal of neuropathology and experimental neurology.

[167]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[168]  Anssi Auvinen,et al.  Incidence of gliomas by anatomic location. , 2007, Neuro-oncology.

[169]  Rebecca A Betensky,et al.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[170]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[171]  M. Teitell,et al.  Reciprocal Regulation of SOCS 1 and SOCS3 Enhances Resistance to Ionizing Radiation in Glioblastoma Multiforme , 2007, Clinical Cancer Research.

[172]  P. Liberski,et al.  Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  A. Donson,et al.  MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma , 2007, Pediatric blood & cancer.

[174]  A. Brandes,et al.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.

[175]  Alejandra Bruna,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[176]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[177]  L. Chin,et al.  Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.

[178]  C. James,et al.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. , 2006, Journal of neurosurgery.

[179]  Gary L Gallia,et al.  PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.

[180]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[181]  S. Shete,et al.  The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. , 2006, Journal of neurosurgery.

[182]  S. Vandenberg,et al.  Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. , 2006, Cancer research.

[183]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[184]  R. Henkelman,et al.  High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. , 2006, Cancer research.

[185]  R. Reddel,et al.  Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. , 2006, Cancer research.

[186]  G. Alí,et al.  Telomerase activity and hTERT mRNA expression in glial tumors. , 2006, International journal of oncology.

[187]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[188]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[189]  E. Holland,et al.  Genetically engineered models have advantages over xenografts for preclinical studies. , 2006, Cancer research.

[190]  D. Hargrave,et al.  Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.

[191]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[192]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[193]  Koji Yoshimoto,et al.  Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.

[194]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[195]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[196]  Dawen Zhao,et al.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.

[197]  Michael Weller,et al.  TP53 promoter methylation in human gliomas , 2005, Acta Neuropathologica.

[198]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[199]  Miguel Alaminos,et al.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.

[200]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[201]  O. Wiestler,et al.  Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. , 2005, Neoplasia.

[202]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[203]  Karlyne M. Reilly,et al.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[204]  F. Apiou,et al.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[205]  P. Kleihues,et al.  Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.

[206]  Eytan Domany,et al.  Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.

[207]  Y. Sawamura,et al.  Expression of the Oligodendroglial Lineage‐Associated Markers Olig1 and Olig2 in Different Types of Human Gliomas , 2003, Journal of neuropathology and experimental neurology.

[208]  M. Weller,et al.  PTEN methylation and expression in glioblastomas , 2003, Acta Neuropathologica.

[209]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[210]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[211]  William A Weiss,et al.  Genetic determinants of malignancy in a mouse model for oligodendroglioma. , 2003, Cancer research.

[212]  D. Gutmann,et al.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.

[213]  Colin C. Collins,et al.  Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors , 2002, Nature Genetics.

[214]  D. Gutmann,et al.  Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation , 2002, Molecular and Cellular Biology.

[215]  I. Pollack,et al.  Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. , 2001, Cancer research.

[216]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[217]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[218]  Yasuhiro Yonekawa,et al.  Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.

[219]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[220]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[221]  E. Holland.  A Mouse Model for Glioma: Biology, Pathology, and Therapeutic Opportunities , 2000, Toxicologic pathology.

[222]  C. James,et al.  Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[223]  J. Moringlane,et al.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. , 1999, Journal of neuropathology and experimental neurology.

[224]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[225]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[226]  K. Sasaki,et al.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. , 1998, Cancer research.

[227]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[228]  J. Costello,et al.  Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines , 1994, Molecular and cellular biology.

[229]  J. Costello,et al.  Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. , 1994, The Journal of biological chemistry.